0001437749-23-016710.txt : 20230711 0001437749-23-016710.hdr.sgml : 20230711 20230606123017 ACCESSION NUMBER: 0001437749-23-016710 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 CORRESP 1 filename1.htm nby20230606_corresp.htm

 

June 6, 2023

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Re:

NovaBay Pharmaceuticals, Inc. (the “Company”)

Form S-1, File No. 333-272304

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended, to become effective as of 5:00 p.m. (Eastern time) on Thursday, June 8, 2023, or as soon as practicable thereafter.

 

 

 

Very truly yours,
     
 

NovaBay Pharmaceuticals, Inc.
     
     
 

By:

/s/ Justin Hall
   

Justin Hall
   

Chief Executive Officer and General Counsel

 

 

cc:         Abby E. Brown, Squire Patton Boggs (US) LLP